Alvaro Lorente-Ros

Dr. Alvaro Lorente-Ros

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2020 in Cardiology Journal
Verified
Journal Article
Closed access
PDF file
ALAlvaro Lorente-Ros
Alvaro Lorente-Ros
JRJuan Manuel Monteagudo Ruiz
Juan Manuel Monteagudo Ruiz
LRLuis M. Rincón
Luis M. Rincón
RPRodrigo Ortega Pérez
Rodrigo Ortega Pérez
SRSonia Rivas
Sonia Rivas
JZJose Luis Zamorano
Jose Luis Zamorano
Background: Despite being associated with worse prognosis in patients with COVID-19, systematic determination of myocardial injury is not recommended. The aim of the study was to study the effect of myocardial injury assessment on risk stratification of COVID-19 patients. Methods: Seven hundred seven consecutive adult patients admitted to a large tertiary hospital with confirmed COVID-19 were included. Demographic data, comorbidities, laboratory results and clinical outcomes were recorded. Charlson comorbidity index (CCI) was calculated in order to quantify the degree of comorbidities. Independent association of cardiac troponin I (cTnI) increase with outcomes was evaluated by multivariate regression analyses and area under curve. In addition, propensity-score matching was performed to assemble a cohort of patients with similar baseline characteristics. Results: In the matched cohort (mean age 66.76 ± 15.7 years, 37.3% females), cTnI increase above the upper limit was present in 20.9% of the population and was associated with worse clinical outcomes, including all-cause mortality within 30 days (45.1% vs. 23.2%; p = 0.005). The addition of cTnI to a multivariate prediction model showed a significant improvement in the area under the time-dependent receiver operating characteristic curve (0.775 vs. 0.756, ΔC-statistic = 0.019; 95% CI 0.001–0.037). Use of renin-angiotensin-aldosterone system inhibitors was not associated with mortality after adjusting by baseline risk factors. Conclusions: Myocardial injury is independently associated with adverse outcomes irrespective of baseline comorbidities and its addition to multivariate regression models significantly improves their performance in predicting mortality. The determination of myocardial injury biomarkers on hospital admission and its combination with CCI can classify patients in three risk groups (high, intermediate and low) with a clearly distinct 30-day mortality. Background: Despite being associated with worse prognosis in patients with COVID-19, systematic determination of myocardial injury is not recommended. The aim of the study was to study the effect of myocardial injury assessment on risk stratification of COVID-19 patients. Methods: Seven hundred seven consecutive adult patients admitted to a large tertiary hospital with confirmed COVID-19 were included. Demographic data, comorbidities, laboratory results and clinical outcomes were recorded. Charlson comorbidity index (CCI) was calculated in order to quantify the degree of comorbidities. Independent association of cardiac troponin I (cTnI) increase with outcomes was evaluated by multivariate regression analyses and area under curve. In addition, propensity-score matching was performed to assemble a cohort of patients with similar baseline characteristics. Results: In the matched cohort (mean age 66.76 ± 15.7 years, 37.3% females), cTnI increase above the upper limit was present in 20.9% of the population and was associated with worse clinical outcomes, including all-cause mortality within 30 days (45.1% vs. 23.2%; p = 0.005). The addition of cTnI to a multivariate prediction model showed a significant improvement in the area under the time-dependent receiver operating characteristic curve (0.775 vs. 0.756, ΔC-statistic = 0.019; 95% CI 0.001–0.037). Use of renin-angiotensin-aldosterone system inhibitors was not associated with mortality after adjusting by baseline risk factors. Conclusions: Myocardial injury is independently associated with adverse outcomes irrespective of baseline comorbidities and its addition to multivariate regression models significantly improves their performance in predicting mortality. The determination of myocardial injury biomarkers on hospital admission and its combination with CCI can classify patients in three risk groups (high, intermediate and low) with a clearly distinct 30-day mortality.

1 January 2025 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
VCVíctor Castro-Urda
Víctor Castro-Urda
MSMelodie Segura-Dominguez
Melodie Segura-Dominguez
DJDiego Jiménez-Sánchez
Diego Jiménez-Sánchez
CACristina Aguilera-Agudo
Cristina Aguilera-Agudo
PVPaula Vela-Martín
Paula Vela-Martín
IFIgnacio Fernández-Lozano
Ignacio Fernández-Lozano
BACKGROUND: Superior vena cava (SVC) has been considered a specific trigger in atrial fibrillation development. METHODS: We investigated the efficacy and safety of combining cryoballoon pulmonary vein isolation (PVI) with SVC ablation compared with PVI alone in 100 patients with paroxysmal or non–long-standing persistent atrial fibrillation. Patients were randomly assigned to either the PVI+SVC ablation group or the PVI-only group. Each patient was given a mobile device to record a daily ECG and detect atrial tachyarrhythmias. RESULTS: The primary end point, freedom from any atrial tachyarrhythmia recurrence between 91 and 365 days post-catheter ablation, did not significantly differ between the 2 groups (62.9% versus 72%; P =0.41). However, the PVI+SVC group exhibited higher rates of phrenic nerve paralysis (20.8% versus 6%; P =0.003) and transient sinus node injury (18.8% versus 0%; P =0.001) compared with the PVI-only group. The median burden of atrial tachyarrhythmia showed no significant difference ( P =0.91). CONCLUSIONS: The addition of SVC ablation to PVI did not enhance freedom from atrial tachyarrhythmia at 12 months, and it led to increased complications. These findings do not support the routine inclusion of SVC ablation in cryoballoon procedures for first-time catheter ablation in patients with paroxysmal or non–long-standing persistent atrial fibrillation.

10 October 2023 in Heliyon
Verified
Journal Article
Open access
JOJosé Avendaño Ortiz
José Avendaño Ortiz
ALAlvaro Lorente-Ros
Alvaro Lorente-Ros
ABAndrea Briones-Figueroa
Andrea Briones-Figueroa
PMPatricia Morán-Alvarez
Patricia Morán-Alvarez
AGAntia García-Fernández
Antia García-Fernández
MGMaría Jesús García-Villanueva
María Jesús García-Villanueva
Acute myocardial infarction (AMI) is associated with systemic inflammatory processes and metabolic alterations. Microbial-derived metabolites, such as short-chain fatty acids and trimethylamine N-oxide (TMAO), have emerged in recent years as key players in the modulation of inflammation, with potential implications for cardiovascular diseases. We performed a prospective observational study that monitored the serological concentration of bacterial metabolites in 45 young patients (<55 years) without cardiovascular risk factors but with AMI, at hospital admission and at 3 months of follow-up, and compared them with a control group. TMAO and acetate levels were significantly higher in AMI, whereas butyrate and propionate were significantly lower. The acetate/propionate ratio showed the most discrimination between AMI and controls by receiver operating characteristic analysis (area under the curve 0.769, P < 0.0001). A multivariate logistic regression model revealed that this ratio was independently associated with AMI. Short-chain fatty acid concentrations, but not TMAO, exhibited significant correlations with inflammatory and coagulation parameters. Three months after the acute AMI event, all metabolite levels returned to those observed in healthy controls except butyrate. In conclusion, our study reveals disturbances of the serological concentration of microbiota-derived metabolites in AMI that are also related to inflammatory and coagulation parameters. These findings highlight an interesting field of study in the potential role of microbial metabolites from gut in cardiovascular disease.

17 August 2022 in JACC: Case Reports
Verified
Journal Article
Open access
ALAlvaro Lorente-Ros
Alvaro Lorente-Ros
EREz-Alddin Rajjoub-Al-Mahdi
Ez-Alddin Rajjoub-Al-Mahdi
JRJuan M. Monteagudo Ruiz
Juan M. Monteagudo Ruiz
SGSonia Rivas García
Sonia Rivas García
RPRodrigo Ortega Pérez
Rodrigo Ortega Pérez
JGJosé L. Zamorano Gómez
José L. Zamorano Gómez
Immune checkpoint inhibitors are associated with a myriad of autoimmune adverse events. We present a 70-year-old patient with renal-cell carcinoma treated with nivolumab/ipilimumab complicated with myocarditis and encephalitis in which gradual impairment of the His-Purkinje system progressed to complete atrioventricular block. Full recovery was achieved after treatment with corticosteroids and immunoglobulins. (Level of Difficulty: Intermediate.)

12 October 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
ALAlvaro Lorente-Ros
Alvaro Lorente-Ros
GAGonzalo L. Alonso-Salinas
Gonzalo L. Alonso-Salinas
JRJuan M. Monteagudo Ruiz
Juan M. Monteagudo Ruiz
MAMaría Abellás-Sequeiros
María Abellás-Sequeiros
JVJosé M. Vieítez-Florez
José M. Vieítez-Florez
JGJosé L. Zamorano Gómez
José L. Zamorano Gómez

3 August 2023 in Resuscitation Plus
Verified
Journal Article
Open access
ALAlvaro Lorente-Ros
Alvaro Lorente-Ros
PSPilar Rubio Soler
Pilar Rubio Soler
DPDavid Curto Prieto
David Curto Prieto
ILIgnacio Fernández Lozano
Ignacio Fernández Lozano